Dyslipidemia in Ischemia/Reperfusion Injury.

Tamara Mazo, Veronica D'Annunzio, Martin Donato, Virginia Perez, Tamara Zaobornyj, Ricardo J Gelpi

Journal: Advances in experimental medicine and biology 2019;1127():117-130

PMID: 31140175

Abstract

Ischemic heart disease is the main cause of morbidity and mortality in the developed world. Although reperfusion therapies are currently the best treatment for this entity, the restoration of blood flow leads, under certain circumstances, to a form of myocardial damage called reperfusion injury. Several studies have shown that age, sex, smoking, diabetes and dyslipidemia are risk factors for cardiovascular diseases. Among these risk factors, dyslipidemias are present in 40% of patients with ischemic heart disease and represent the clinical factor with the greatest impact on the prognosis of patients with cardiovascular diseases. It is known that during reperfusion the increase of the oxidative stress is perhaps one of the most important mechanisms implicated in cell damage. That is why several researchers have studied protective mechanisms against reperfusion injury, such as the ischemic pre- and post- conditioning, making emphasis mainly on the reduction of oxidative stress. However, few of these efforts have been successfully translated into the clinical setting. The controversial results in regards to the relation between cardioprotective mechanisms and dyslipidemia/hypercholesterolemia are mainly due to the difference among quality, composition and the time of administration of hypercholesterolemic diets, as well as the difference in the species used in each of the studies. Therefore, in order to compare results, it is crucial that all variables that could modify the obtained results are taken into consideration.

Address: Institute of Cardiovascular Physiopathology and Department of Pathology and Institute of Biochemistry and Molecular Medicine (IBIMOL UBA-CONICET), Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.; Institute of Biochemistry and Molecular Medicine (IBIMOL UBA-CONICET) School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.; Institute of Cardiovascular Physiopathology and Department of Pathology and Institute of Biochemistry and Molecular Medicine (IBIMOL UBA-CONICET), Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina. [email protected].

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.